Postoperative Bisphosphonates Use is Associated with Reduced Adverse Outcomes After Primary Total Joint Arthroplasty of Hip and Knee: A Nationwide Population-Based Cohort Study

Overview

Journal Calcif Tissue Int

Specialty Pathology

Date 2024 Mar 16

PMID 38492035

Authors

Jen-Ta Shih

Timothy L Tan

Pei-Hung Shen

Tsu-Te Yeh

Chia-Chun Wu

Ru-Yu Pan

Wu-Chien Chien

Chi-Hsiang Chung

Sheng-Hao Wang

Affiliations

Soon will be listed here.

Abstract

Bisphosphonates have been associated with a decreased risk of revision surgery after total joint arthroplasty of the hip or knee (TJA) because of their effects on decreased periprosthetic bone loss and prosthetic migration. However, the results in the early literature are inconsistent, and the influence of bisphosphonates on associated complications and subsequent TJA remains unknown. This study investigated the association between the use of bisphosphonates and the risk of adverse outcomes after primary TJA. This matched cohort study utilized the National Health Insurance Research Database in Taiwan to identify patients who underwent primary TJA over a 15-year period (January 2000-December 2015 inclusive). Study participants were further categorized into two groups, bisphosphonate users and nonusers, using propensity score matching. The Kaplan-Meier curve analysis and adjusted hazard ratios (aHRs) of revision surgery, adverse outcomes of primary surgery and subsequent TJA were calculated using Cox regression analysis. This study analyzed data from 6485 patients who underwent total hip arthroplasty (THA) and 20,920 patients who underwent total knee arthroplasty (TKA). The risk of revision hip and knee arthroplasty was significantly lower in the bisphosphonate users than in the nonusers (aHR, 0.54 and 0.53, respectively). Furthermore, the risk of a subsequent total joint arthroplasty, adverse events and all-cause mortality were also significantly reduced in the bisphosphonate users. This study, involving a large cohort of patients who underwent primary arthroplasties, revealed that bisphosphonate treatment may potentially reduce the risk of revision surgery and associated adverse outcomes. Furthermore, the use of bisphosphonates after TJA is also associated with a reduced need for subsequent arthroplasty.Research Registration Unique Identifying Number (UIN): ClinicalTrials.gov Identifier-NCT05623540 ( https://clinicaltrials.gov/show/NCT05623540 ).

Citing Articles

Evidence-based joint statement position of perioperative bone optimization in the arthroplasty candidate, from FEMECOT, AMMOM, ACOMM, SCCOT, SECOT, SEFRAOS, SEIOMM.

Enrique L, Francisco T, Inigo E, Cristina O, Francisco L, Angel G Osteoporos Int. 2025; 36(3):375-389.

PMID: 39934392 DOI: 10.1007/s00198-025-07411-6.

Incidence of Total Knee Arthroplasty in Older Females with Knee Osteoarthritis and Osteoporosis Treated with Denosumab Compared with Those Treated Using Bisphosphonates: A Population-Based Cohort Study.

Yu T, Wu W, Lee R, Chen I, Wang J, Wen S Life (Basel). 2025; 14(12.

PMID: 39768410 PMC: 11677198. DOI: 10.3390/life14121704.

A Bone Health Optimization Framework for Malaysia: a position paper by the Malaysian Bone Health Optimization Network (MyBONe).

Lee J, Leong J, Thong F, Sharifudin M, Abbas A, Kamudin N Arch Osteoporos. 2024; 19(1):88.

PMID: 39304537 DOI: 10.1007/s11657-024-01448-6.

References

Chen A, Gupte C, Akhtar K, Smith P, Cobb J . The Global Economic Cost of Osteoarthritis: How the UK Compares. Arthritis. 2012; 2012:698709. PMC: 3467755. DOI: 10.1155/2012/698709. View

Vos T, Flaxman A, Naghavi M, Lozano R, Michaud C, Ezzati M . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2163-96. PMC: 6350784. DOI: 10.1016/S0140-6736(12)61729-2. View

Murray C, Dellavalle R, Danaei G, Fahimi A, Flaxman D, Gabriel S . The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310(6):591-608. PMC: 5436627. DOI: 10.1001/jama.2013.13805. View

Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M . The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014; 73(7):1323-30. DOI: 10.1136/annrheumdis-2013-204763. View

Zhang W, Moskowitz R, Nuki G, Abramson S, Altman R, Arden N . OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008; 16(2):137-62. DOI: 10.1016/j.joca.2007.12.013. View

Harris W, Sledge C . Total hip and total knee replacement (1). N Engl J Med. 1990; 323(11):725-31. DOI: 10.1056/NEJM199009133231106. View

Murphy L, Helmick C, Schwartz T, Renner J, Tudor G, Koch G . One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage. 2010; 18(11):1372-9. PMC: 2998063. DOI: 10.1016/j.joca.2010.08.005. View

Losina E, Thornhill T, Rome B, Wright J, Katz J . The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic. J Bone Joint Surg Am. 2012; 94(3):201-7. PMC: 3262184. DOI: 10.2106/JBJS.J.01958. View

Kurtz S, Ong K, Lau E, Mowat F, Halpern M . Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am. 2007; 89(4):780-5. DOI: 10.2106/JBJS.F.00222. View

10.

Patel A, Pavlou G, Mujica-Mota R, Toms A . The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset. Bone Joint J. 2015; 97-B(8):1076-81. DOI: 10.1302/0301-620X.97B8.35170. View

11.

Havelin L, Engesaeter L, Espehaug B, Furnes O, Lie S, Vollset S . The Norwegian Arthroplasty Register: 11 years and 73,000 arthroplasties. Acta Orthop Scand. 2000; 71(4):337-53. DOI: 10.1080/000164700317393321 . View

12.

Vasso M, Beaufils P, Cerciello S, Panni A . Bone loss following knee arthroplasty: potential treatment options. Arch Orthop Trauma Surg. 2014; 134(4):543-53. DOI: 10.1007/s00402-014-1941-8. View

13.

Abu-Amer Y, Darwech I, Clohisy J . Aseptic loosening of total joint replacements: mechanisms underlying osteolysis and potential therapies. Arthritis Res Ther. 2007; 9 Suppl 1:S6. PMC: 1924521. DOI: 10.1186/ar2170. View

14.

Russell R . Bisphosphonates: the first 40 years. Bone. 2011; 49(1):2-19. DOI: 10.1016/j.bone.2011.04.022. View

15.

Shanbhag A . Use of bisphosphonates to improve the durability of total joint replacements. J Am Acad Orthop Surg. 2006; 14(4):215-25. DOI: 10.5435/00124635-200604000-00003. View

16.

Hilding M, Aspenberg P . Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. Acta Orthop. 2008; 78(6):795-9. DOI: 10.1080/17453670710014572. View

17.

Hilding M, Aspenberg P . Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop. 2007; 77(6):912-6. DOI: 10.1080/17453670610013213. View

18.

Thillemann T, Pedersen A, Mehnert F, Johnsen S, Soballe K . Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010; 46(4):946-51. DOI: 10.1016/j.bone.2010.01.377. View

19.

Prieto-Alhambra D, Javaid M, Judge A, Murray D, Carr A, Cooper C . Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011; 343:d7222. PMC: 3232250. DOI: 10.1136/bmj.d7222. View

20.

Teng S, Yi C, Krettek C, Jagodzinski M . Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies. PLoS One. 2015; 10(10):e0139927. PMC: 4596810. DOI: 10.1371/journal.pone.0139927. View